Effect of Dexamethasone on Ciprofibrate-lnduced Cell Proliferation and Peroxisome Proliferation. RAO, M. S., AND SUBBARAO, V. (1997). Fundam. Appl. Toxicol. 35,[78][79][80][81][82][83] Peroxisome proliferators cause liver cell proliferation in addition to other pleiotropic effects such as peroxisome proliferation and induction of certain peroxisomal and cytosolic enzymes in liver. Since dexamethasone has been shown to inhibit mitogen-induced liver cell hyperplasia, we examined whether dexamethasone inhibits only cell proliferation without affecting peroxisome proliferation induced by peroxisome proliferators such as ciprofibrate. Livers of rats fed a diet containing ciprofibrate (0.025%) with or without added dexamethasone (0.5 mg or 1 mg/kg diet) for 1 week were evaluated for hepatocyte proliferation and peroxisome proliferation. Dexamethasone administration resulted in abrogation of ciprofibrate-induced cell proliferation as shown by bromodeoxyuridine (BrdU) labeling and mitoses counts. The hepatocyte proliferative index measured after administration of a single dose of BrdU was 18.3 ± 1.1 and 2.3 ± 0.7% (/? < 0.01) in ciprofibrate and ciprofibrate + dexamethasone treated rats, respectively. With multiple injections of BrdU (daily injections for 7 days) the proliferative index was 225 ± 10 and 183 ± 2% (p < 0.02), respectively, in these two groups. Interestingly, whereas the levels of peroxisome proliferator-induced M, 80,000 polypeptide and catalase and peroxisomal bifunctional enzyme, and the corresponding mRNAs and peroxisome volume density were unaffected. These results show that dexamethasone selectively inhibits only cell proliferation without inhibiting the peroxisome proliferation caused by ciprofibrate. This model should be useful for examining the role of cell proliferation versus oxidative stress in peroxisome proliferatorinduced hepatOCarcinOgeneSJS.
ministration of peroxisome proliferators causes hepatocellular carcinomas (Reddy et al, 1980; Rao and Reddy, 1987) . Since peroxisome proliferators are nongenotoxic, the mechanism by which they cause liver tumors remains controversial. The suggested mechanisms include oxidative stress resulting from sustained induction of H 2 O 2 generating peroxisomal fatty acyl-CoA (Reddy and Rao, 1989) and increased cell proliferation (Butterworth et al., 1992) . To resolve the issue of the primacy of oxidative stress versus cell proliferation in peroxisome proliferator-induced hepatocarcinogenesis, an experimental model is needed in which the cell proliferative and peroxisome proliferative properties can be dissociated.
Hepatocyte proliferation is induced either after cell loss (partial hepatectomy or necrosis caused by hepatotoxic agents), referred to as compensatory hyperplasia, or after mitogen stimulation (lead nitrate, ethylene bromide, etc.), referred to as direct hyperplasia (Fausto and Webber, 1994; Ledda-Columbano et al, 1992) . It has been shown that during compensatory hyperplasia there is activation of immediate early genes and production of cytokines and growth factors (Fausto and Webber, 1994) . The mitogeninduced liver cell hyperplasia appears to be dependent mostly on tumor necrosis factor-a (TNFa) and not other factors (Coni et al, 1993; Shinozuka et al, 1994) . The glucocorticoid dexamethasone has been shown to inhibit mitogen-induced liver cell proliferation through abrogation of TNFa production (Ledda-Columbano et al, 1994) . Since peroxisome proliferators also induce liver cell proliferation through a mitogenic effect without causing liver cell necrosis, we hypothesized that dexamethasone inhibits only cell proliferation, and not the peroxisome proliferation induced by ciprofibrate, a potent peroxisome proliferator. The results demonstrate that dexamethasone prevents cell proliferation in liver but not the peroxisome proliferation induced by ciprofibrate in the rat.
METHODS
Male F-344 rats were obtained from Charles River Laboratories (Wilmington, MA) and housed in plastic cages on San-i-cel bedding in an airconditioned room with a 12-hr dark and light cycle Aftera week of acclimatization, rats were divided into six groups (4 to 8 rats/group) and fed a Downloaded from https://academic.oup.com/toxsci/article-abstract/35/1/78/1649990 by guest on 23 February 2019 diet containing ciprofibrate (0.025%; Sterling-Winthrop Research Institute, Rensselaer, NY) and/or dexamethasone (Sigma) for 7 days as follows: group 1, control diet; group 2, ciprofibrate; group 3. ciprofibrate + dexamethasone (1 mg/kg diet); group 4. ciprofibrate + dexamethasone (0.5 mg/ kg diet); group 5, dexamethasone (1 mg/kg diet); and group 6, dexamethasone (0.5 mg/kg diet). At the beginning of experiments rats weighed between 80 and 90 g. At the end of 7 days all animals were given bromodeoxyuridine (BrdU) intraperitoneally (100 mg/kg body weight) 1 hr prior to euthanization. In addition, 16 rats of the same age and weight were divided into four equal groups and fed a diet containing ciprofibrate, ciprofibrate + dexamethasone (0.5 mg/kg diet), dexamethasone (0.5 mg/kg diet), and control diet for 7 days. These animals were given daily ip injections of BrdU (100 mg/kg body weight), a total of seven doses, and euthanized 1 hr after the last injection. At the time of euthanization body weights and liver weights were obtained and portions of liver were used for light microscopy, electron microscopy, preparation of postnuclear fraction, and total RNA. Quantitative data were analyzed by Student's r test.
Morphometric analysis of peroxisome.
Fragments of liver from four rats in each group were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, for 4 hr and processed for transmission electron microscopy. Thin sections were cut on an LKB ultratome. stained with uranyl acetate and lead citrate, and examined in a JOEL JEM-100CS 11 electron microscope. Morphometric analysis of peroxisomes was carried out as described before (Rao et al, 1982) , according to the procedure of Weibel et al. (1966) . Briefly, micrographs were taken at X5000 and magnified 2.5 times at printing. Points of intersection overlying cytoplasm and peroxisomes were counted using a 5-mm-spaced lattice grid. The volume density of peroxisomes was determined in relation to cytoplasmic volume. Ten photographs were counted from each animal.
Analysis of proliferative indices. For BrdU immunohistochemistry, portions of liver from all animals were fixed in 70% alcohol overnight at 4°C and processed for light microscopy. Five-micrometer-thick paraffin sections were stained immunohistochemically by the avidin-biotin-peroxidase complex method using Vectastain ABC reagent (Vector Laboratories, Burlingame, CA) with monoclonal antibodies specific for BrdU (BectonDickenson) at a dilution of I in 300 (Ward et al, 1988) . The reaction product was visualized with the addition of diaminobenzidine tetrahydrochloride and the slides were counterstained with hematoxylin. The labeling index was obtained by counting 2000 hepatocytes in each liver.
To obtain a mitotic index 2000 hepatocytes were counted from each liver on hematoxylin and eosin stained sections.
SDS-polyacrylamide gel electrophoresis.
Ten percent (W/V) liver homogenates were prepared in ice-cold 0.25 M sucrose containing 10 rriM EDTA (pH 7.5) using a Potter-Elvehjem homogenizer. Postnuclear fractions were obtained by centrifuging the homogenate at 700^ for 10 min in a Beckman J-21 centrifuge at 4°C The protein concentration in the homogenate was determined by the method of Lowry et al. (1951) . Electrophoresis was performed on 10% SDS-polyacrylamide slab gels according to the method of Laemmli (1970) , using 30 y.% protein (Nemali et al., 1988) . After completion of the electrophoretic run (20 mA/slab), the proteins were fixed by immersing the gels in 10% trichloroacetic acid for 30 min and then stained with 0.1% Coomassie blue in 50% methanol/10% acetic acid.
Northern blot analysis. Total RNA was extracted from livers using the method of guanidinium thiocyanate-phenol -chloroform extraction (Chomczynski and Sacchi, 1987) . Electrophoresis of glyoxal-denatured total RNA (30 /ig) in 1% agarose gel and transfer to nitrocellulose filters were performed (Heilman et al., 1982) . Filters were hybridized with nick-translated 32 P-labeled catalase and peroxisomal bifunctional enzyme (PBE) cDNA at 42°C for 18 hr (Nemali et al, 1988) . The filters were washed in 2x SSC/ 0.1% SDS at room temperature for 2 hr, dried, and exposed to film at -70°C. The relative mass of specific RNAs was measured by densitometric scanning of the autoradiographs.
RESULTS
Body and liver weights, proliferative index of hepatocytes, and peroxisome volume density in rats given ciprofibrate diet with or without dexamethasone are presented in Table 1 . Body weight gain in control rats and rats fed diet containing ciprofibrate and ciprofibrate + dexamethasone (0.5 mg/kg diet) increased approximately by 52, 34, and 13%, respectively, in 7 days, whereas no weight gain was observed in rats that were fed diet containing higher dose of dexamethasone. As expected, ciprofibrate treatment caused a significant increase in relative liver weight when compared to that of controls (9.0 g vs 4.7 g/100 g body weight, p < 0.001). Similarly, rats that received both dexamethasone and ciprofibrate also showed a significant increase in absolute and relative liver weights over those of controls. In rats that were fed diet containing only dexamethasone there was no increase in absolute liver weight, although the relative weight increased by 36 to 60% due to a relative reduction in body weight gain.
BrdU, a pyrimidine analogue, is incorporated into DNA synthesizing nuclei and can be easily identified immunohistochemically using anti-BrdU antibodies. Immunohistochemical studies performed after administration of single or multiple doses of BrdU demonstrated a significant increase in the number of labeled hepatocytes in rats given ciprofibrate, when compared to controls and rats given ciprofibrate + dexamethasone diet (Figs, la and lb). The labeling index of hepatocytes after pulse labeling for 1 hr was 18.3 and 8.5/2000 in ciprofibrate treated and control rats, respectively (p < 0.01). Interestingly, in rats given dexamethasone and ciprofibrate or dexamethasone alone there was a marked decrease in the number of labeled cells. Dexamethasone at 0.5 mg and 1 mg/kg diet dose levels completely prevented ciprofibrate-induced cell proliferation. In the dexamethasone-treated groups the labeling indices ranged from 2 to 5/2000 cells. It is not clear why the 0.5 mg dexamethasone dose level caused more inhibition of cell proliferation than the 1 mg dose level. In rats that were given multiple doses of BrdU the labeling index was 164,225, 183, and 41/2000 cells in the control, ciprofibrate, and ciprofibrate + dexamethasone groups, respectively. Similarly, the mitotic index was also 5-to 12-fold higher in the ciprofibrate group when compared to the dexamethasone + ciprofibrate group (Table 1) .
Ultrastructural analysis of hepatocytes from rats fed diet containing ciprofibrate alone or ciprofibrate and dexamethasone (1 mg/kg diet) showed a marked increase in the number of peroxisomes (Figs. 2a and 2b ). Morphometric analysis in both the groups revealed a 10-fold increase in the volume density of peroxisomes over that of control animals (p < 0.001), which received normal chow or chow containing dexamethasone (1 mg/kg diet).
SDS-PAGE analysis of postnuclear fractions prepared from livers of different groups is shown in Fig. 3 . In rats treated with ciprofibrate alone or ciprofibrate and dexamethasone, a marked increase in the amount of peroxisome proliferator-induced M, 80,000 polypeptide (PPA-80) was noted, whereas in control groups the level of this polypeptide was very low. Northern blot analysis of total RNA obtained from livers of ciprofibrate or ciprofibrate and dexamethasone showed a marked increase in the levels of PBE mRNA and a slight increase in catalase mRNA (Figs. 4 and 5) . Quantitative analysis of PBE and catalase mRNA signals by densitometry revealed a 10-to 12-fold and a 1.5-fold increase, respectively, in these groups when compared with the control groups. The levels of PPA-80 and mRNAs of PBE and catalase in the 0.5 and 1 mg dexamethasone + ciprofibrate groups were comparable.
DISCUSSION
The present study, which was designed to examine the effect of the glucocorticoid dexamethasone on ciprofibrateinduced peroxisome proliferation and hepatocyte proliferation, clearly demonstrates that dexamethasone inhibits cell proliferation without affecting the peroxisome proliferation and PBE induction caused by ciprofibrate. Peroxisome volume density and the levels of catalase and PBE mRNAs were identical in the ciprofibrate group and the dexamethasone + ciprofibrate groups. These findings indicate that dexamethasone did not inhibit activation of the peroxisome proliferatoractivated receptor isoforms implicated in the modulation of peroxisome proliferator-induced pleiotropic effects. Nonetheless, the effect of dexamethasone on ciprofibrate-induced cell proliferation was completely different. Dexamethasone at both dose levels (0.5 mg and 1 mg/kg diet), as revealed by immunohistochemistry after administration of a single dose and multiple doses of BrdU, completely abrogated the cell proliferation induced by ciprofibrate. In addition, dexamethasone also suppressed cell proliferation in control rats.
Liver cell proliferation is dependent on a multitude of regeneration signals derived from hepatic and extrahepatic sources. These signals include hormones, growth factors, and cytokines (Bucher. 1995; Fausto el at, 1995) . It appears that cytokines and growth factors play a major role during compensatory hyperplasia, whereas cytokine TNFa mostly plays a crucial role during mitogen-induced direct hyperplasia (Fausto and Webber, 1994; Coni et al., 1993; Shinozuka et al., 1994) . TNFa that is produced by Kupffer cells in the liver, through a paracrine effect, stimulates transcription factor (NF-KB), leading to priming of hepatocytes (Censue et al., 1991; Fausto and Webber, 1994) . In addition, it has also been shown that TNFa induces DNA synthesis in cultured hepatocytes (Beyer and Theologides, 1993) . Dexamethasone, a known inhibitor of TNFa, was shown to inhibit mitogen-induced liver cell proliferation (Ledda-Columbano et al., 1994) . Remick et al. (1989) have shown that dexamethasone markedly reduced TNF induction caused by lipopolysacharide in mice. It is possible that inhibition of ciprofibrate-induced cell proliferation by dexamethasone is also through inhibition of TNFa. Earlier studies have shown that peroxisome proliferators cause proliferation of both hepatocytes and Kupffer cells (Ward et al., 1988; Rao, personal observation) . In this study we have noticed a marked decrease in the number of labeled Kupffer cells in the dexamethasone and ciprofibrate group when compared to that of the ciprofibrate treated group (data not shown).
We have presented an experimental model where perox- 1 -3) . dexamethasone (lanes 4-6), ciprofibrate and dexamethasone (lanes 7-9), and ciprofibrate (lanes 10-12) treated rats. The size of PBE mRNA is 3 kb. FIG. 5. Northern blot analysis for catalase mRNA in livers of rats from different groups (lanes same as in Fig. 4) . The size of catalase mRNA is 2.4 kb.
isome proliferator-induced cell proliferation was selectively inhibited without affecting peroxisome proliferation and induction of peroxisomal enzymes. This model should serve as an ideal system for investigating the role of oxidative stress in peroxisome proliferator-induced hepatocarcinogenesis.
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